Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels

Summary

Current therapy for haemophilia A is guided by severity of the disease, which in turn is best reflected in patients' endogenous factor VIII activity levels. For patients with severe haemophilia (particularly children), prophylaxis with continuous routine factor replacement has become standard of care in developed countries and is gradually becoming the standard of care in developing countries. The question arises then: what is an appropriate prophylaxis regimen to prevent bleeding events and arthropathy, while also maximizing patient quality of life and taking into consideration the costs of prophylaxis? Should all patients be treated with one standard, fixed prophylaxis regimen, or should prophylaxis be individualised for each patient? If so, what factors need to be considered in choosing the appropriate dose and frequency of factor administration? If prophylaxis is tailored to the individual patient, then patient-related factors (bleeding phenotype, activity profiles, age, joint status) and product-specific factors (half-life of the replacement factor in the individual patient) will determine the choice of regimen, whether it be a fixed-regimen prophylaxis or prophylaxis that is tailored to patient activity and bleeding risk. Regardless of the choice of prophylaxis regimen, for any regimen to be effective, adherence to therapy is key to optimising outcomes.

Keywords

FVIII - prophylaxis - phenotype - dose - frequency

^* International Network of Pediatric Hematologists

• References

• 1 Blanchette VS, Key NS, Ljung LR. et al. Definitions in haemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935-1939.
• 2 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al. Guidelines for the management of haemophilia. Haemophilia 2013; 19: e1-e47.
• 3 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77) 3-132.
• 4 Collins PW, Blanchette VS, Fischer K. et al. rAHF-PFM Study Group. Breakthrough bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009; 7: 413-420.
• 5 Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
• 6 Aronstam A, Kirk PJ, McHardy J. et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977; 30: 65-67.
• 7 Biggs R, Macfarlane RG. Haemophilia and related conditions: a survey of 187 cases. Br J Haematol 1958; 4: 1-27.
• 8 van Dijk K, Fischer K, van der Bom JG. et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11: 438-443.
• 9 Hang MX, Blanchette VS, Pullenayegum E. et al. Age at first joint bleed and bleeding severity in boys with severe haemophilia A: Canadian Haemophilia Primary Prophylaxis Study. J Thromb Haemost 2011; 9: 1067-1069.
• 10 Carcao MD, van den Berg HM, Ljung R. et al. Correlation between phenotype and genotype in a large unselected cohort of children with severe haemophilia A. Blood 2013; 121: 3946-3952, S1.
• 11 van Dijk K, van der Bom JG, Fischer K. et al. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004; 92: 305-310.
• 12 van Dijk K, van der Bom JG, Fischer K. et al. Phenotype of severe haemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost 2007; 5: 1062-1064.
• 13 Vlot AJ, Mauser-Bunschoten EP, Zarkova AG. et al. The half-life of infused factor VIII is shorter in haemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000; 83: 65-69.
• 14 Denis CV, Christophe OD, Oortwijn BD. et al. Clearance of von Willebrand factor. Thromb Haemost 2008; 99: 271-278.
• 15 Lundin B, Ljung R, Pettersson H. et al. MRI scores of ankle joints in children with haemophilia--comparison with clinical data. Haemophilia 2005; 11: 116-122.
• 16 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535-544.
• 17 den Uijl I, Biesma D, Grobbee D. et al. Outcome in moderate haemophilia. Blood Transfus 2014; 12 (Suppl. 01) s330-s336.
• 18 Blanchette VS, Key NS, Ljung LR. et al. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Definitions in haemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935-1939.
• 19 Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-978.
• 20 Ahnstrom J, Berntorp E, Lindvall K. et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-697.
• 21 Astermark J, Petrini P, Tengborn L. et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-1113.
• 22 Fischer K, van der Bom JG, Mauser-Bunschoten EP. et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia. Blood 2002; 99: 2337-2341.
• 23 Kreuz W, Escuriola-Ettingshausen C, Funk M. et al. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Haemophilia 1998; 4: 413-417.
• 24 Nilsson IM, Berntorp E, Lofqvist T. et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
• 25 Carlsson M, Berntorp E, Bjorkman S. et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
• 26 Fischer K, Steen Carlsson K, Petrini P. et al. Intermediate-dose versus high-dose prophylaxis for severe haemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-1136.
• 27 Feldman BM, Pai M, Rivard GE. et al. Tailored prophylaxis in severe haemophilia A: interim results from the first 5 years of the Canadian Haemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-1236.
• 28 Kraft J, Blanchette V, Babyn P. et al. Magnetic resonance imaging and joint outcomes in boys with severe haemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012; 10: 2494-2502.
• 29 Collins PW, Blanchette VS, Fischer K. et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009; 7: 413-420.
• 30 den Uijl I, Biesma D, Grobbee D. et al. Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?. Blood Transfus 2013; 11: 364-369.
• 31 den Uijl IE, Fischer K, Van Der Bom JG. et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17: 41-44.
• 32 den Uijl IE, Mauser Bunschoten EP, Roosendaal G. et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia 2011; 17: 849-853.
• 33 Krishnan S, Vietri J, Furlan R. et al. Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey. Haemophilia 2015; 21: 64-70.
• 34 Collins PW, Bjorkman S, Fischer K. et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-275.
• 35 Kepa S, Horvath B, Reitter-Pfoertner S. et al. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia 2015; 21: 343-350.
• 36 van Dijk K, van der Bom JG, Lenting PJ. et al. Factor VIII half-life and clinical phenotype of severe haemophilia A. Haematologica 2005; 90: 494-498.
• 37 Blanchette VS, Shapiro AD, Liesner RJ. et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-1326.
• 38 Tarantino MD, Collins PW, Hay CR. et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-437.
• 39 Fischer K, Collins P, Bjorkman S. et al. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia 2011; 17: 433-438.
• 40 Broderick CR, Herbert RD, Latimer J. et al. Association between physical activity and risk of bleeding in children with haemophilia. J Am Med Assoc 2012; 308: 1452-1459.
• 41 Bjorkman S, Collins P. Project on Factor VIII/Factor IX Pharmacokinetics of the Factor VIII/Factor IX Scientific and Standardisation Committee of the ISTH. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2013; 11: 180-182.
• 42 Oldenburg J, Albert T. Novel products for haemostasis – current status. Haemophilia 2014; 20 (Suppl. 04) 23-28.
• 43 Mahlangu J, Powell JS, Ragni MV. et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe haemophilia A. Blood 2014; 123: 317-325.
• 44 Coyle TE, Reding MT, Lin JC. et al. Phase I study of BAY 94–9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with haemophilia A. J Thromb Haemost 2014; 12: 488-496.
• 45 Young G, Mahlangu J, Kulkarni R. et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe haemophilia A. J Thromb Haemost 2015; 13: 967-977.
• 46 Collins PW, Young G, Knobe K. et al. paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in haemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124: 3880-3886.
• 47 Powell JS, Apte S, Chambost H. et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol 2015; 168: 124-134.
• 48 Manco-Johnson MJ. Collision sports and risk of bleeding in children with haemophilia. J Am Med Assoc 2012; 308: 1480-1481.
• 49 Ross C, Goldenberg NA, Hund D. et al. Athletic participation in severe haemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics 2009; 124: 1267-1272.
• 50 Blanchette VS, Manco-Johnson M, Santagostino E. et al. Optimising factor prophylaxis for the haemophilia population: where do we stand?. Haemophilia 2004; 10: 97-104.
• 51 Barnes C. Importance of pharmacokinetics in the management of haemophilia. Pediatr Blood Cancer 2013; 60 (Suppl. 01) S27-S29.
• 52 van den Berg HM, Fischer K, Mauser-Bunschoten EP. et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-565.